# A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-

Source: https://onco.cc/trials/nct05816252/  
OnCo record `nct05816252` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Klus Pharma Inc., active and no longer recruiting.

## Summary

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) is a phase 2 interventional study registered as NCT05816252 by Klus Pharma Inc., with 356 participants enrolled, started 2023-04-19 and due to reach its primary completion in 2026-06-30. Interventions recorded: SKB264, Pembrolizumab, Carboplatin, Osimertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05816252
- Phase: 2
- Setting: A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer
- Sponsor: Klus Pharma Inc.
- Enrolled: 356

## Sources

- ClinicalTrials.gov NCT05816252: https://clinicaltrials.gov/study/NCT05816252

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05816252.json